Perioperative pharmacology in morbid obesity

Current Opinion in Anaesthesiology

Volumn 23, Issue 4, 2010, Pages 485-491

  Lemmens, Hendrikus J M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

obesity; pharmacodynamics; pharmacokinetics

Indexed keywords

ANESTHETIC AGENT; ATRACURIUM; CISATRACURIUM; DESFLURANE; FENTANYL; ISOFLURANE; NEOSTIGMINE; PANCURONIUM; PROPOFOL; REMIFENTANIL; ROCURONIUM; SEVOFLURANE; SUFENTANIL; SUGAMMADEX; SUXAMETHONIUM; THIOPENTAL; VECURONIUM; CENTRAL MUSCLE RELAXANT; CHOLINESTERASE INHIBITOR; DRUG; INHALATION ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT;

ADIPOSE TISSUE; ANESTHESIA INDUCTION; BODY FAT; BODY MASS; BODY SURFACE; BODY WEIGHT; BRADYCARDIA; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; EXTRACELLULAR FLUID; HEART OUTPUT; HUMAN; HYPOTENSION; INHALATION ANESTHESIA; LEAN BODY WEIGHT; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORBID OBESITY; NEUROMUSCULAR BLOCKING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; DOSE RESPONSE; METABOLISM; PHARMACOKINETICS; PHARMACOLOGY; PHYSIOLOGY;

ANALGESICS, OPIOID; ANESTHETICS; ANESTHETICS, INHALATION; ANIMALS; BODY MASS INDEX; BODY WEIGHT; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCLE RELAXANTS, CENTRAL; NEOSTIGMINE; OBESITY, MORBID; PERIOPERATIVE CARE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 77954658375     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833b0a8c     Document Type: Review

References (38)

1. Wada DR, Bjorkman S, Ebling WF, et al. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 1997; 87:884-899.
2. Bjorkman S, Wada DR, Stanski DR. Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients. Anesthesiology 1998; 88:657-667.
3. Bjorkman S, Wada DR, Berling BM, Benoni G. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90:1226-1241.
4. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82:505-508.
5. Collis T, Devereux RB, Roman MJ, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001; 103:820-825.
6. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78:657-665.
7. La Colla L, Albertin A, La Colla G, et al. No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. Eur J Anaesthesiol 2009; 26:362-369.
8. James W. Research on obesity. London: Her Majesty's Stationery Office; 1976.
9. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44:1051-1065.
10. Jung D, Mayersohn M, Perrier D, et al. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 1982; 56:269-274.
11. Upton RN, Ludbrook GL, Grant C, Martinez AM. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. Anesth Analg 1999; 89:545-552.
12. Upton RN, Ludbrook G. A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man. Anesthesiology 2005; 103:344-352.
13. Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ('pharmacokinetic mass'). Anesthesiology 2004; 101:603-613.
14. Slepchenko G, Simon N, Goubaux B, et al. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology 2003; 98:65-73.
15. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89:562-573.
16. La Colla L, Albertin A, La Colla G, et al. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet 2010; 49:131-139.
17. Lemmens HJ, Saidman LJ, Eger EI 2nd, Laster MJ. Obesity modestly affects inhaled anesthetic kinetics in humans. Anesth Analg 2008; 107:1864-1870.
18. Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 1967; 23:621-630.
19. Yasuda N, Lockhart SH, Eger EI 2nd, et al. Kinetics of desflurane, isoflurane, and halothane in humans. Anesthesiology 1991; 74:489-498.
20. Torri G, Casati A, Albertin A, et al. Randomized comparison of isoflurane and sevoflurane for laparoscopic gastric banding in morbidly obese patients. J Clin Anesth 2001; 13:565-570.
21. Strum EM, Szenohradszki J, Kaufman WA, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. Anesth Analg 2004; 99:1848-1853.
22. De Baerdemaeker LE, Struys MM, Jacobs S, et al. Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an 'inhalation bolus' technique. Br J Anaesth 2003; 91:638-650.
23. Arain SR, Barth CD, Shankar H, Ebert TJ. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. J Clin Anesth 2005; 17:413-419.
24. Vallejo MC, Sah N, Phelps AL, et al. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. J Clin Anesth 2007; 19:3-8.
25. La Colla L, Albertin A, La Colla G, Mangano A. Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. Br J Anaesth 2007; 99:353-358.
26. Casati A,Marchetti C, Spreafico E, Mamo D. Effects of obesity on wash-in and wash-out kinetics of sevoflurane. Eur J Anaesthesiol 2004; 21:243-245.
27. McKay RE, Malhotra A, Cakmakkaya OS, et al. Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. Br J Anaesth 2010; 104:175-182.
28. Bilotta F, Doronzio A, Cuzzone V, et al. Early postoperative cognitive recovery and gas exchange patterns after balanced anesthesia with sevoflurane or desflurane in overweight and obese patients undergoing craniotomy: a prospective randomized trial. J Neurosurg Anesthesiol 2009; 21:207-213.
29. Torri G, Casati A, Comotti L, et al. Wash-in and wash-out curves of sevoflurane and isoflurane in morbidly obese patients. Minerva Anestesiol 2002; 68:523-527.
30. Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology 1982; 57:48-49.
31. Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438-442.
32. Puhringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16:507-510.
33. Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99:1086-1089.
34. Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109:787-792.
35. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74:515-518.
36. Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090-1094.
37. Tsueda K, Warren JE, McCafferty LA, Nagle JP. Pancuronium bromide requirement during anesthesia for the morbidly obese. Anesthesiology 1978; 48:438-439.
38. Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97:160-163.